DALLAS, July 24, 2020 /PRNewswire/ -- Lantern Pharma
(NASDAQ: LTRN), a clinical stage biotechnology company using
its proprietary RADR® artificial intelligence ("A.I.") platform to
improve drug discovery and development and, identify patients who
will benefit from its portfolio of targeted oncology therapeutics,
announced today that it will host a conference call and live
webcast on Thursday, July 30, 2020 at
8:00 a.m. Eastern Time to discuss
financial and operating results for the second quarter ended
June 30, 2020.
The call will be led by Panna
Sharma, President and Chief Executive Officer. He will be
joined on the call by other members of the management team.
Interested participants and investors may access the conference
call via teleconference or online.
Conference Call & Webcast
Details
Toll-free Domestic &
Canada: 800.791.4813 –
conference ID 10552
International: 785-424-1102 – conference ID 10552
US and Canada callers one touch
dial: +1.800.791.4813, 10552#
The webcast will be available in the "Investors" section of
the company website at https://ir.lanternpharma.com/ under the News
& Events page.
Replay Details
A replay of the conference call
will be available for 30 days following the call thru August 30, 2020.
Replay Number: 1-888-567-0053, no passcode will be
needed.
A live audio-only webcast and related presentation materials
will also be accessible on the Lantern Pharma corporate website:
https://ir.lanternpharma.com/. Web participants are encouraged to
register 15 minutes prior to the start of the call. The webcast
will be archived on the Lantern Pharma website for 6 months.
About Lantern Pharma
Lantern Pharma is a clinical-stage biopharmaceutical company
innovating the repurposing, revitalization and development of
precision therapeutics in oncology. We leverage advances in machine
learning, genomics, and artificial intelligence by using a
proprietary A.I. platform to discover biomarker signatures that
help identify patients more likely to respond to our pipeline of
cancer therapeutics. Lantern's focus is to improve the outcome for
patients by leveraging our technology to uncover, rescue and
develop abandoned or failed drugs. Our current pipeline of three
drugs, two in clinical stages and one in preclinical, focuses on
cancers that have unique and unmet clinical needs with a clearly
defined patient population. We believe that the use of machine
learning, genomics and computational methods can help accelerate
the revitalization, refocusing and development of small
molecule-based therapies. By targeting drugs to patients whose
genomic profile identifies them as having the highest probability
of benefiting from the drug, this approach represents the potential
to deliver best-in-class outcomes. Our team seeks out experienced
industry partners, world-class scientific advisors, and innovative
clinical-regulatory approaches to assist in delivering cancer
therapies to patients as quickly and efficiently as possible. For
more information, please visit the company's website at
www.lanternpharma.com or follow the company on Twitter
@lanternpharma.
Contact
Marek
Ciszewski, JD
Director, Investor Relations
628-777-3167
investor@lanternpharma.com
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. The forward-looking statements in this press release
include, among other things, statements relating to: the potential
advantages of our RADR® platform in identifying drug
candidates and patient populations that are likely to respond to a
drug candidate; our strategic plans to advance the development of
any of our drug candidates; our strategic plans to expand the
number of data points that our RADR® platform can access
and analyze; our research and development efforts of our internal
drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline the drug development process and to identify
patient populations that would likely respond to a drug candidate;
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Additional
information regarding the risk factors to which we are subject is
provided in greater detail in our final prospectus, dated
June 10, 2020, for our initial public
offering, on file with the Securities and Exchange Commission.
You may access our June 10, 2020
final prospectus under the investor SEC filings tab of our website
at www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-to-host-second-quarter-2020-operating-and-financial-results-conference-call-on-july-30-2020-301099389.html
SOURCE Lantern Pharma